CJC-1295 + Ipamorelin

Overview

The CJC-1295 + Ipamorelin combination is one of the most-requested GH-axis blends in the catalog and one of the most-cited dual-pathway formulations in research and academic workflows. The two peptides act on parallel signaling pathways that converge on somatotroph GH release: CJC-1295 (no DAC, the Modified GRF 1-29 form) is a GHRH-receptor agonist mimicking the hypothalamic GHRH input, while Ipamorelin is a selective GHSR (ghrelin receptor) agonist mimicking the alternative ghrelin-pathway input. The dual-pathway combination produces GH-release magnitudes substantially larger than either component alone at comparable individual doses, the synergy is the entire rationale for the combination. Lyochem supplies the CJC-1295 + Ipamorelin blend as a co-lyophilized vial at ≥99.0% HPLC purity for each component. The standard ratio is 1:1 by mass (5+5 mg in a 10 mg vial); custom ratios (2+5, 5+10, 10+10) and larger total fills are available through the OEM service. Co-lyophilization is preferred over solution-phase mixing because both components are short-half-life peptides where ratio stability matters operationally and the co-lyophilized form locks the ratio at the lyophilization step. The release packet certifies both component purities individually plus the actual ratio in the released vial.

Who buys this, and why

GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.

Primary buyer fit: research laboratories that have validated this peptide into their workflow and research groups studying topical / aesthetic-pharmacology applications.

Specifications

CAS

(blend)

Purity (HPLC)

≥ 99.0% per component

Common vial sizes

10 mg

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion analysis (acetate vs TFA)
• Stability at −20 °C across 12 months
• Solubility in BAC water / PBS reconstitution

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.

Frequently asked questions